CPT code 0484U designates a Proprietary Laboratory Analyses (PLA) assay for detection of macrolide resistance–associated mutations in the 23S rRNA gene of Mycoplasma genitalium. This single-source molecular test from MedArbor Diagnostics and SpeeDx Inc. uses oral, rectal, or vaginal swabs to identify mutations that predict resistance to macrolide antibiotics, informing antimicrobial selection. Nationally, PLA codes like 0484U matter because they track use of manufacturer-specific diagnostics that have implications for coding, billing, and clinical decision-making.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes payer coverage patterns, coding and billing considerations for proprietary molecular tests, and clinical context around Mycoplasma genitalium macrolide resistance testing.

Readers will learn: a concise definition of the test and its clinical purpose; the typical service setting and specimen types; payer landscape and which major payers are addressed; common modifiers reported with the service (Modifiers 00, 22, 52, 53); and areas where Data not available in the input limit further detail (for example, associated taxonomies, specific ICD-10 diagnoses, and related codes). The content focuses on coding and clinical context relevant to providers, laboratories, and billing professionals working with proprietary molecular diagnostics.